58662-54-7

Usage

Uses

Used in Pharmaceutical Industry:
5-(Benzyloxy)-2-Nitrobenzaldehyde is used as an intermediate in the synthesis of 5-Hydroxyindole-3-Acetic Acid-13C3 (H953604), which is an isotope-labeled analog of 5-hydroxyindole-3-acetic acid. 5-(BENZYLOXY)-2-NITROBENZALDEHYDE is an impurity found in chlorpheniramine (C424300), an antihistaminic agent. The use of 5-(Benzyloxy)-2-Nitrobenzaldehyde in this context is essential for the development and production of pharmaceuticals that target histamine-related conditions, such as allergies and other immune responses.

Upstream product

• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 90151-04-5 4-hydroxy-2-nitrobenzaldehyde 
• 59342-81-3 ethyl (3-formyl-4-nitrophenyl) carbonate 
• 68423-35-8 ethyl (3-formylphenyl) carbonate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 92438-11-4 benzyl-[4-nitro-3-(trans-2-nitro-vinyl)-phenyl]-ether 
• 61340-15-6 5-(benzyloxy)-2-nitrobenzoic acid 
• 68423-37-0 2-Nitro-5-(benzyloxy)-benzylchlorid 
• 453518-17-7 1-(5-benzyloxy-2-nitrophenol)-2-propen-1-ol 
• 68423-36-9 (5-(benzyloxy)-2-nitrophenyl)methanol 
• 1373152-17-0 C₁₄H₁₂N₂O₄ 
• 625119-87-1 (5-benzyloxy-2-nitrophenyl)ethene 
• 1613082-42-0 7-(benzyloxy)-10-(4-methoxyphenyl)-9-(2-(4-methoxyphenylamino)-4,4-dimethyl-6-oxocyclohex-1-enyl)-3,3-dimethyl-3,4,9,10-tetrahydroacridin-1(2H)-one 
• 499973-08-9 N-(5-benzyloxy-2-nitrobenzoyl)-L-proline methyl ester 
• 863870-46-6 4-benzyloxy-2-(2,2-dibromovinyl)phenylamine 
• 463363-06-6 1-hydroxy-4-methoxy-8-benzyloxy-5H-indeno[1,2-b]indol-10-one 
• 463363-16-8 2,4-dimethoxy-8-benzyloxy-5H-indeno[1,2-b]indol-10-one 
• 887645-19-4 5,6-dimethoxy-2-(2-nitro-5-benzyloxyphenyl)indane-1,3-dione 
• 887645-20-7 4,6-dimethoxy-2-(2-nitro-5-benzyloxyphenyl)indane-1,3-dione 

Relevant academic research and scientific papers

ESTROGEN RECEPTOR-MODULATING COMPOUNDS

Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode

Butyrylcholinesterase (BChE) is a promising target for the treatment of later stage cognitive decline in Alzheimer's disease. A set of pseudo-irreversible BChE inhibitors with high selectivity over hAChE was synthesized based on carbamates attached to tetrahydroquinazoline scaffolds with the 2-thiophenyl compound 2p as the most potent inhibitor of eqBChE (KC = 14.3 nM) and also of hBChE (KC = 19.7 nM). The inhibitors transfer the carbamate moiety onto the active site under release of the phenolic tetrahydroquinazoline scaffolds that themselves act as neuroprotectants. By combination of kinetic data with molecular docking studies, a plausible binding model was probed describing how the tetrahydroquinazoline scaffold guides the carbamate into a close position to the active site. The model explains the influence of the carrier scaffold onto the affinity of an inhibitor just before carbamate transfer. This strategy can be used to utilize the binding mode of other carbamate-based inhibitors.

Step-economical synthesis of tetrahydroquinolines by asymmetric relay catalytic Friedlaender condensation/transfer hydrogenation

Two steps in one reaction: The title relay reaction relies on a combination of an achiral Lewis acid and a chiral Bronsted acid (B-H in the scheme). This one-pot method provides access to tetrahydroquinoline derivatives with multiple continuous stereogeni

NOVEL CURCUMIN DERIVATIVE

To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH═CH.

Bronsted acid-catalyzed enantioselective Friedlaender condensations: Achiral amine promoter plays crucial role in the stereocontrol

A highly enantioselective Friedlaender condensation has been established by using chiral Bronsted acids in combination with achiral amines to give quinolines in high yields (up to 99%) and with excellent enantioselectivities (up to 95%).

NOVEL CURCUMIN DERIVATIVE

The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.

A highly selective tandem cross-coupling of gem-dihaloolefins for a modular, efficient synthesis of highly functionalized indoles

(Chemical Equation Presented) A highly efficient method of indole synthesis using gem-dihalovinylaniline substrates and an organoboron reagent was developed via a Pd-catalyzed tandem intramolecular amination and an intermolecular Suzuki coupling. Aryl, alkenyl, and alkyl boron reagents are all successfully employed, making for a versatile modular approach. The reaction tolerates a variety of substitution patterns on the aniline leading to indoles with group at C2-C7. The orthogonal approach of the sequential copper- and palladium-mediated synthesis of 1,2-diarylindoles exploited the wide availability of diverse organoboron reagents.

A new class of histamine H3 receptor antagonists derived from ligand based design

Design and synthesis of highly potent and selective non-imidazole inverse agonists for the histamine H3 receptor is described. The study validates a new pharmacophore model based on the merging of two previously described models. It also demonstrates that the removal of the basic center potentially interacting with ASP3.32 and common to both models leads to loss of activity, whereas the replacement of the second basic center by an acceptor retains the potency.

GLUCOKINASE ACTIVATORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of wherein the variables are as defined herein.

New ligands at the?melatonin binding site MT3

The third melatonin binding site, MT3 is a non-classical one since it is not a seven transmembrane domains receptor, but an enzyme, quinone reductase 2. A major concern for the study of the physiological role of this site is the lack of specific ligands, permitting to more accurately dissect the pathways linked to the activation of MT3. Indeed, in the course of finding new ligands, we identified a new series of compounds with affinity to the binding site in the nM range, particularly 2,3-dimethoxy 7-hydroxy 10-methyl 5H 10H indeno(1,2-b)indol-10-one (DMHMIO), with a Ki of 190 pM. Based on slightly different and novel synthons compared to most of the compounds used in melatonin pharmacology studies, these compounds offer new perspective for the description of the melatonin pathways, so much more by not having any affinity towards the MT1 and MT2 'classical' melatonin receptors.